http://www.reportbuyer.com/rss.htmlIn this category you can find business reports on Pharmaceutical Deals & Alliances, information includes Company Agreement overviews and Partnering Guides.en-gbReportbuyerservice@reportbuyer.comenquiries@redwiredesign.comhttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/partnering_agreements_diagnostics.htmlThe report provides a detailed understanding and analysis of how and why companies enter diagnostic partnering deals. The majority of deals are development stage whereby the licensee obtains a right or an option right to license the licensors diagnostic technology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes. f6bd6312fc57421fb4d248f69db7bf91Tue, 01 Sep 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/manufacturing_supply_agreements_pharma_biotech_diagnostics.htmlThe Manufacturing and Supply Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the manufacturing and supply agreements entered into by the worlds leading biopharma companies. This report provides details of the latest manufacturing and supply agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of manufacturing and supply agreements from 2003 to early 2009. f52b4f15f6b8ecba36e69c7d4e6d92e8Tue, 07 Jul 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/oncology_partnering_agreements_pharma_biotech_diagnostics.htmlThe Oncology Partnering Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the oncology partnering agreements entered into by the worlds leading biopharma companies. The report provides a detailed understand and analysis of how and why companies enter oncology partnering deals. The majority of deals are discovery, preclinical or clinical whereby the licensee obtains a right or an option right to license the licensors oncology technology or product candidates. 96bea778a81bdb18bcd23f1b66dc134aWed, 17 Jun 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/practical_guide_finding_partners_pharma_biotech.htmlCurrentPartnering's Practical Guide to Finding Partners in Pharma & Biotech provides a comprehensive overview of all the steps required to identify and secure partnering either for an in-licensing or out-licensing activity. The report takes the reader through the practical steps required to prepare for partnering, prepare supporting materials, identify and shortlist potential partners and opportunities, identifying and contacting the right person in the partner company, and managing of discussions through to deal negotiation. In addition, the report provides a detailed overview of the activities a business development executive and a company should be undertaking to build and maintain an extensive contact network, and to become partner of choice, respectively. 19783e0aeb2a67c5c984a0f78840e706Wed, 01 Apr 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/option_evaluation_agreements_pharma_biotech.htmlReport description The Option and Evaluation Agreements in Pharma and Biotech report provides comprehensive understanding and unprecedented access to the option and evaluation partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest option and evaluation agreements announced in the pharmaceutical and biotechnology sectors. Detailed and comprehensive, the report provides details of option and evaluation agreements from 2003 to end 2008. c5a218caac7d916f4f963e3de01041e7Tue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/evolving_trends_biopharmaceutical_licensing_deal_assessments_drivers_resistors.htmlEvolving Trends in Biopharmaceutical Licensing: Deal assessments, drivers and resistors Large Pharma companies have become heavily dependant upon alliances and in-licensing to gain access to technologies/new molecular entities from Biopharma. This reliance has strengthened Biopharma's bargaining position, and is reflected in negotiation tactics which aim to expand their role beyond product discovery and development towards an active participation in the the future of their products. This is emphasized by the growing complexity of licensing deals, as Biopharma attempts to secure marketing and commercialization rights within partnership deals. 0954f54119141d189859f7a17238e4ffTue, 03 Mar 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/merger_acquisition_agreements_pharma_biotech_diagnostics.htmlWelcome to the revised and updated Merger and Acquisition Agreements in Pharma, Biotech and Diagnostics report. The report provides a detailed understand and analysis of how and why companies enter merger and acquisition deals. The majority of deals are acquisitions whereby the acquirer acquires the target company in a cash and/or equity transaction. 6a2ab1375d8abd9f87fb564bd03e54f2Mon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/co_promotion_co_marketing_agreements_pharma_biotech_diagnostics.htmlThe Co-promotion and Co-marketing Agreements in Pharma, Biotech and Diagnostics report provides comprehensive understanding and unprecedented access to the co-promotion and co-marketing partnering agreements entered into by the worlds leading biopharma companies. This report provides details of the latest co-promotion and co-marketing agreements announced in the pharmaceutical, biotechnology and diagnostic sectors. Fully revised and updated, the report provides details of co-promotion and co-marketing agreements from 2003 to end 2008. c5d5c76cb08baa3835aa6582c676fb48Mon, 02 Feb 2009 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/strategic_alliances_world_pharma_biotech_markets.htmlIn the last decade or so, strategic alliances and partnerships among pharmaceutical and biotech companies have doubled to around 700 per year per sector, although most of this increase came in the early years. Regardless of its size, every pharma or biotech company has certain limitations in their own research although usually they have enough capacity in development to bring new compounds to the market very effectively. However, on a number of occasions, the inhouse development capacity may get prioritized in favor of other products within the company's portfolio. 0d59728cb91ed93ef2096c4b70f1ace0Tue, 11 Nov 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/product_asset_purchase_agreements_pharma_biotech_diagnostics.htmlThe Product and Asset Purchase Agreements in Pharma, Biotech and Diagnostics report provides detailed understanding and analysis of how and why companies enter asset purchase deals. The report provides a detailed understanding and analysis of how and why companies enter business, product, technology and royalty assets. The focus of the report is on partnerships for business, product, technology and royalty assets where partners have entered an agreement to dispose of or acquire said assets. 5eba8046e262c084126005bb9a81162aTue, 11 Nov 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/pre_clinical_stage_partnering_agreements_biopharma.htmlThe Pre-clinical Stage Partnering Agreements in Biopharma report detailed understanding and analysis of how and why companies enter pre-clinical stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter pre-clinical stage licensing/business development and other forms of partnering arrangement. The focus of the report is on partnerships for pre-clinical stage compounds where partners have joined forces to exploit these early stage opportunities. ac24e8cdfa552850b810aff3a94ba0d9Fri, 10 Oct 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/discovery_stage_partnering_agreements_biopharma.htmlThe Discovery Stage Partnering Agreements in Biopharma report detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The report provides a detailed understanding and analysis of how and why companies enter discovery stage licensing/business development and other forms of partnering arrangement. The focus of the report is on partnerships for discovery technologies and discovery stage compounds where partners have joined forces to exploit these early stage opportunities. 834a90741513eadc2434261c895f66f6Mon, 01 Sep 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/otsuka_partnering_guide_2008.htmlReport description  The Otsuka Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand Otsuka and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. 2cd0e3e21bc5787de01a68f1a408db57Mon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/boehringer_ingelheim_partnering_guide_2008.htmlReport description The Boehringer Ingelheim Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand Boehringer Ingelheim and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. d1c854f86d19702ab2b93509da1fd2e5Mon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/genentech_partnering_guide_2008.htmlReport description The Genentech Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand Genentech and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. 5e7ed92c301858c0d197108697c4a69eMon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/merck_partnering_guide_2008.htmlReport description The Merck & Co Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand Merck & Co and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. dd89125744b588cf1b0b863c1a2f675dMon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/proctergamble_partnering_guide_2008.htmlReport description The Procter & Gamble Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand Procter & Gamble and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. 2ab36db2c3fcb68aee7ff43957a96967Mon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/csl_partnering_guide_2008.htmlReport description The CSL Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand CSL and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. 770d008127ae76e1976e5a7fb464014aMon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/barr_pharmaceuticals_partnering_guide_2008.htmlReport description  The Barr Pharmaceuticals Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand Barr Pharmaceuticals and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. 57aa1f5021ee2743aa44fa92c4b97fb8Mon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Allianceshttp://www.reportbuyer.com/pharma_healthcare/deals_alliances/licensing/takeda_partnering_guide_2008.htmlReport description The Takeda Partnering Guide 2008 provides an in-depth insight into the partnering interests and activites of one of the worlds leading biopharma companies. This report provides all the information you require to better understand Takeda and its partnering interests and activities over the past five years. One of the key aspects of partnering is finding those companies that are potential partners for the development and commercialization of the next generation of therapies as developed by innovative biopharma R&D companies. 95bfbf1745e55e81e2ba9886996e0c2aMon, 21 Jul 2008 12:00:00 GBPharma & Healthcare/Deals & Alliances